The "Collaboration Deals in Pharmaceuticals 2019-2024" report has been added to ResearchAndMarkets.com's offering.
This report provides a detailed understanding and analysis of how and why companies enter collaboration deals.
- Understand deal trends since 2019
- Browse collaboration deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
The report provides access to collaboration deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual collaboration contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Analyzing contract agreements allows due diligence of:
- What are the rights granted or optioned?
- What rights are granted by the agreement?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are intellectual property rights handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What subcollaboration and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Companies Featured in the Report
- 2cureX
- 3B Pharmaceuticals
- 3D Medicines
- 3SBio
- 3T Biosciences
- 4B Technologies
- 4C Biomed
- 4D Pharma
- 4P-Pharma
- 7 Hills Pharma
- 9 Meters Biopharma
- 22nd Century
- 23andMe
- 48Hour Discovery
- 111
- A*STAR Singapore Immunology Network
- A2 Biotherapeutics
- Aachen University
- Abbisko Therapeutics
- Abbott Laboratories
- Abbvie
- AbCellera Biologics
- Abdul Latif Jameel Health
- Abilita Bio
- ABL Bio
- AbSci
- ACADIA Pharmaceuticals
- AC Bioscience
- Acceleron Pharma
- Accent Therapeutics
- Accenture
- Access to Comprehensive Genomic Profiling Coalition
- ACEA Therapeutics
- Acerand Therapeutics
- Acerta Pharma
- Acer Therapeutics
- Ache
- Actelion
- Actinium Pharmaceuticals
- Actuate Therapeutics
- Acumen Analytics
- Acumen Pharmaceuticals
- Adagene
- Adapsyn Bioscience
- Adaptimmune
- Adaptive Biotechnologies
- Adaptive Phage Therapeutics
- ADC Therapeutics
- Addex Therapeutics
- Adimab
- and 1,900 more!
For more information about this report visit https://www.researchandmarkets.com/r/infy00
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241009709099/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
